Doxazosin/Finasteride

多沙唑嗪/非那雄胺

Report date: 2025/07/29 14:30:29

Base Information

Drug NameDoxazosin/Finasteride
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionAdrenergic receptor alpha-1 antagonistsSteroid 5 alpha reductase inhibitors
TargetsAdrenergic receptors alpha-1Steroid 5 alpha reductase
Therapy Area/IndicationsProstatic Hyperplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes FinasterideDoxazosin Mesylate
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesShinpoong
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShinpoong
Active IndicationsN/A
Inactive IndicationsProstatic Hyperplasia

Other Information

ATC CodeN/A
Related LinksN/A